Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
Silke Gillessen(Institute of Oncology Research), Robert E. Reiter(University of California, Los Angeles), Darren M.C. Poon(Institute of Cancer Research), Kim N.(Asian Institute of Technology), Karim Fizazi(Université de Lille), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Anders Bjartell(Lund University), Michael J. Morris(Dana-Farber Cancer Institute), Felix Y. Feng(University of Michigan), Robert G. Bristow(Princess Margaret Cancer Centre), Nicholas D. James(Royal Marsden NHS Foundation Trust), Charles G. Drake(Columbia University Irving Medical Center), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Raja B. Khauli(American University of Beirut Medical Center), Ignacio Durán(Instituto de Biomedicina de Sevilla), Ravindran Kanesvaran(University of Ioannina), Raya Leibowitz‐Amit(The University of Texas MD Anderson Cancer Center), Maha Hussain(Northwestern University), Anwar R. Padhani(Mount Vernon Cancer Centre), Himisha Beltran(Dana-Farber Cancer Institute), Axel Heidenreich(Centrum für Integrierte Onkologie), Tomasz M. Beer(Exact Sciences (United States)), Joe M. O’Sullivan(San Antonio College), Vedang Murthy(Homi Bhabha National Institute), Susan Halabi(Duke Medical Center), Nicolas Mottet(Centre Hospitalier Universitaire de Saint-Étienne), Philip W. Kantoff(Convergent Science (United States)), Hind Mrabti(Institut National d'Oncologie), Stefano Fanti(Azienda USL di Bologna), Martin Gleave(University of British Columbia), Michael S. Hofman(Peter MacCallum Cancer Centre), Colin C. Pritchard(Animal and Plant Health Agency), Ian D. Davis(Austin Health), Noel W. Clarke(The Christie NHS Foundation Trust), Mark Frydenberg(Monash University), Alicia K. Morgans(Dana-Farber Cancer Institute), Johann S. de Bono(Royal Marsden NHS Foundation Trust), William Oh(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Piet Ost(Ghent University Hospital), Christopher P. Evans(University of Nevada, Reno), Chris Parker(Royal Marsden NHS Foundation Trust), Declan G. Murphy(Peter Doherty Institute), Alberto Bossi(Institut Gustave Roussy), Daniel Heinrich(San Antonio College), Fernando Cotait Maluf(Hospital Israelita Albert Einstein), Chris Logothetis(The University of Texas MD Anderson Cancer Center), Gerhardt Attard(London Cancer), Robin Millman(MRC Clinical Trials Unit at UCL), Celestia S. Higano(University of British Columbia)
Cited by 396
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k